A Feasibility Study of a Physical Activity Intervention in Older Adult Inpatients With Acute Leukemia
OBJECTIVES:
Primary
- To test the feasibility of conducting a physical activity intervention in hospitalized
older adults with acute myeloid leukemia (AML) undergoing induction or reinduction
chemotherapy.
Secondary
- To obtain preliminary data regarding the effectiveness of a physical activity
intervention on physical function, quality of life, and treatment-related symptoms in
these patients.
OUTLINE: Patients undergo a baseline evaluation in week 1 focusing on basic demographics,
health, physical function and quality-of-life assessments. These assessments include the
Short Physical Performance Battery (SPPB); the Hand Grip Test of Muscular Strength; the
Demographics and Physical Activity History; the Functional Assessment of Cancer Therapy
(FACT-Leu); the Distress Thermometer; the Short-form Positive Affect Schedule (PANAS-SF);
the Satisfaction with Life Scale (SWL); the FAST-23 Disability Measure; the Center for
Epidemiologic Studies Depression Scale Short Form (CES-D); the Self-efficacy for Physical
Activity Scale; the Intervention Feedback Form; and the Pre-Post Session Ratings. Some
medical data may be obtained from the patient's medical record to assist in these
assessments.
Beginning in weeks 2-5, patients undergo a 30-minute orientation to the exercise sessions
that will be tailored to individual needs and abilities. Patients undergo a 30- to 45-minute
group physical activity session twice a week, and a supervised individual session following
the same format as the group session, once a week for 4 weeks. After completion of the
physical activity intervention, patients complete an activities packet and repeat the
physical function and quality of life assessments in weeks 5-6 and again upon readmission
for consolidation therapy in weeks 9-13 .
After completion of study intervention, patients are followed for 4 months.
Interventional
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Percentage of adults 50 years of age or older admitted for induction or reinduction chemotherapy for acute myeloid leukemia (AML) who are eligible for the study
day 1
No
Suzanne C. Danhauer, PhD
Study Chair
Comprehensive Cancer Center of Wake Forest University
United States: Institutional Review Board
CDR0000573938
NCT00554489
July 2007
April 2011
Name | Location |
---|---|
Wake Forest University Comprehensive Cancer Center | Winston-Salem, North Carolina 27157-1096 |